Cyclacel Pharmaceuticals, Inc. (CYCC)

Market Cap	2.14M
Revenue (ttm)	74,000
Net Income (ttm)	-13.48M
Shares Out	6.29M
EPS (ttm)	-6.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,168
Open	0.349
Previous Close	0.346
Day's Range	0.335 - 0.353
52-Week Range	0.300 - 4.000
Beta	0.35
Analysts	Strong Buy
Price Target	11.00 (+3,135.29%)
Earnings Date	Mar 18, 2025

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kina...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCC
• Website: https://www.cyclacel.com

Analyst Forecast

According to one analyst, the rating for CYCC stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(3,135.29% upside)

Analyst Consensus: Strong Buy